Is intensive drug therapy appropriate for older patients?
Gollub
S B
SB
Division of Cardiovascular Diseases, Kansas University School of Medicine, Kansas City 66160, USA.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000209:etiology; D003362:Cost-Benefit Analysis; D004363:Drug Utilization; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015996:Survival Rate; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000191:economics
D000319:Adrenergic beta-Antagonists; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin